Article Trunk



Chemistry / M2 Pharma, “Bluebird bio Presents Updated Data of LentiGlobin Gene Therapy in Patients with Severe Sickle Cell Disease.”

06.21.2018 · Posted in Uncategorized
M2 PHARMA-June 21, 2018-Bluebird bio Presents Updated Data of LentiGlobin Gene Therapy in Patients with Severe Sickle Cell Disease (C)2018 M2 COMMUNICATIONS
  • Cambridge, Massachusetts-based gene therapies specialist bluebird bio, Inc. (NASDAQ: BLUE) has discussed new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy...

Leave a Reply

You must be logged in to post a comment.

%d bloggers like this: